Budd–Chiari syndrome and veno-occlusive disease/sinusoidal obstruction syndrome

• Published in: Gut Vol. 57; no. 10; pp. 1469 - 1478
• Main Author: Valla, D-C
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group Ltd and British Society of Gastroenterology 01.10.2008; BMJ; BMJ Publishing Group LTD
• Subjects: Anticoagulants - therapeutic use; Biological and medical sciences; Blood; Budd-Chiari Syndrome - drug therapy; Congenital diseases; Gastroenterology. Liver. Pancreas. Abdomen; Hepatic Veins - physiopathology; Hepatic Veno-Occlusive Disease - drug therapy; Humans; Laboratories; Liver - drug effects; Liver - physiology; Liver diseases; Liver. Biliary tract. Portal circulation. Exocrine pancreas; Medical sciences; Metabolism; Metabolites; Mortality; Mutation; Other diseases. Semiology; Risk Factors; Rodents; Stem cells; Thrombosis; Toxicity; Transplants & implants; Vascular disease; Venoocclusive disease; Budd-Chiari syndrome; Portal circulation disease; Gastroenterology; Cardiovascular disease; Digestive diseases; Venous disease
• ISSN: 0017-5749; 1468-3288
• DOI: 10.1136/gut.2007.133637

In Asia or South Africa, an increased risk of IVC obstruction has been shown in patients with a very poor standard of living, although the mechanisms underlying this increased risk remain unknown. 8 Last, but not least, it has been shown that BCS was a rare complication in patients affected with a known MPD, 7 or with other known prothrombotic factors. [...]the reason why only rare patients with these underlying conditions develop BCS has remained unexplained. [...]convincing evidence for its efficacy is still lacking. [...]in practice, management of VOD/SOS in haematopoietic stem cell recipients still relies mainly on non-specific measures, including prevention and treatment of fluid overload, prevention and treatment of sepsis, and careful consideration of the risk-benefit ratio of drug administration.